Gregory R Stettler1, Ernest E Moore2, Hunter B Moore1, Geoffrey R Nunns1, Benjamin R Huebner1, Peter Einersen1, Arsen Ghasabyan3, Christopher C Silliman4, Anirban Banerjee1, Angela Sauaia5. 1. Department of Surgery, University of Colorado School of Medicine, Denver, CO. 2. Department of Surgery, University of Colorado School of Medicine, Denver, CO; Denver Health Medical Center, University of Colorado School of Medicine, Denver, CO. Electronic address: ernest.moore@dhha.org. 3. Denver Health Medical Center, University of Colorado School of Medicine, Denver, CO. 4. Department of Surgery, University of Colorado School of Medicine, Denver, CO; Department of Pediatrics, University of Colorado School of Public Health, Denver, CO; Bonfils Blood Center, University of Colorado School of Public Health, Denver, CO. 5. Department of Surgery, University of Colorado School of Medicine, Denver, CO; Department of Health Systems, Management & Policy, University of Colorado School of Public Health, Denver, CO.
Abstract
BACKGROUND: Thrombelastography platelet mapping is a useful assay to assess antiplatelet therapy. Inhibited response to the adenosine diphosphate receptor on platelets occurs early after injury, but recent work suggests this alteration occurs even with minor trauma. However, the utility of thrombelastography platelet mapping, specifically the percent of adenosine diphosphate receptor inhibition, in predicting outcomes and guiding platelet transfusion in trauma-induced coagulopathy remains unknown We assessed the role of percent of adenosine diphosphate-inhibition in predicting survival, requirement for massive transfusion or platelet transfusion in patients at risk for trauma-induced coagulopathy. METHODS: Thrombelastography platelet mapping was assessed in 303 trauma activation patients from 2014-2016 and in 89 healthy volunteers. Percent of adenosine diphosphate-inhibition is presented as median and interquartile range. We compared the area under the receiver operating characteristic curve of percent of adenosine diphosphate-inhibition, platelet count, and rapid thrombelastography maximum amplitude for in-hospital mortality, massive transfusion (>10 red blood cells or death/6 hours), and platelet transfusion (>0 platelet units or death/6 hour). RESULTS: Overall, 35 (11.5%) patient died, 27 (8.9%) required massive transfusion and 46, platelet transfusions (15.2%). Median percent of adenosine diphosphate-inhibition was 42.5% (interquartile range: 22.4-69.1%), compared with 4.3 % (interquartile range: 0-13.5%) in healthy volunteers (P < .0001). Patients that died, had a massive transfusion, or platelet transfusion had higher percent of adenosine diphosphate-inhibition than those that did not (P < .05 for all). However, percent of adenosine diphosphate-inhibition did not add significantly to the predictive performance of maximum amplitude or platelet count for any of the 3 outcomes, after adjustment for confounders. Subgroup analyses by severe traumatic brain injury, severe injury and requirement of red blood cells showed similar results. CONCLUSION: Adenosine diphosphate receptor inhibition did not add predictive value to predicting mortality, massive transfusion, or platelet transfusion. Thus, the role of thrombelastography platelet mapping as a solitary tool to guide platelet transfusions in trauma requires continued refinement.
BACKGROUND: Thrombelastography platelet mapping is a useful assay to assess antiplatelet therapy. Inhibited response to the adenosine diphosphate receptor on platelets occurs early after injury, but recent work suggests this alteration occurs even with minor trauma. However, the utility of thrombelastography platelet mapping, specifically the percent of adenosine diphosphate receptor inhibition, in predicting outcomes and guiding platelet transfusion in trauma-induced coagulopathy remains unknown We assessed the role of percent of adenosine diphosphate-inhibition in predicting survival, requirement for massive transfusion or platelet transfusion in patients at risk for trauma-induced coagulopathy. METHODS: Thrombelastography platelet mapping was assessed in 303 trauma activationpatients from 2014-2016 and in 89 healthy volunteers. Percent of adenosine diphosphate-inhibition is presented as median and interquartile range. We compared the area under the receiver operating characteristic curve of percent of adenosine diphosphate-inhibition, platelet count, and rapid thrombelastography maximum amplitude for in-hospital mortality, massive transfusion (>10 red blood cells or death/6 hours), and platelet transfusion (>0 platelet units or death/6 hour). RESULTS: Overall, 35 (11.5%) patient died, 27 (8.9%) required massive transfusion and 46, platelet transfusions (15.2%). Median percent of adenosine diphosphate-inhibition was 42.5% (interquartile range: 22.4-69.1%), compared with 4.3 % (interquartile range: 0-13.5%) in healthy volunteers (P < .0001). Patients that died, had a massive transfusion, or platelet transfusion had higher percent of adenosine diphosphate-inhibition than those that did not (P < .05 for all). However, percent of adenosine diphosphate-inhibition did not add significantly to the predictive performance of maximum amplitude or platelet count for any of the 3 outcomes, after adjustment for confounders. Subgroup analyses by severe traumatic brain injury, severe injury and requirement of red blood cells showed similar results. CONCLUSION:Adenosine diphosphate receptor inhibition did not add predictive value to predicting mortality, massive transfusion, or platelet transfusion. Thus, the role of thrombelastography platelet mapping as a solitary tool to guide platelet transfusions in trauma requires continued refinement.
Authors: Lisa M Brown; Mariah S Call; M Margaret Knudson; Mitchell J Cohen; J B Holcomb; C E Wade; K J Brasel; G Vercruysse; J MacLeod; R P Dutton; J R Hess; J C Duchesne; N E McSwain; P Muskat; J Johannigamn; H M Cryer; A Tillou; J F Pittet; M A De Moya; M A Schreiber; B Tieu; S Brundage; L M Napolitano; M Brunsvold; M Brunsvold; G Beilman; A B Peitzman; M S Zenait; J Sperry; L Alarcon; M A Croce; J P Minei; R Kozar; E A Gonzalez; R M Stewart; S M Cohn; J E Mickalek; E M Bulger; B A Cotton; T C Nunez; R Ivatury; J W Meredith; P Miller; G J Pomper; B Marin Journal: J Trauma Date: 2011-08
Authors: Peter M Einersen; Ernest E Moore; Michael P Chapman; Hunter B Moore; Eduardo Gonzalez; Christopher C Silliman; Anirban Banerjee; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2017-01 Impact factor: 3.313
Authors: Matthew E Kutcher; Brittney J Redick; Ryan C McCreery; Ian M Crane; Molly D Greenberg; Leslie M Cachola; Mary F Nelson; Mitchell Jay Cohen Journal: J Trauma Acute Care Surg Date: 2012-07 Impact factor: 3.313
Authors: Francis J Castellino; Michael P Chapman; Deborah L Donahue; Scott Thomas; Ernest E Moore; Max V Wohlauer; Braxton Fritz; Robert Yount; Victoria Ploplis; Patrick Davis; Edward Evans; Mark Walsh Journal: J Trauma Acute Care Surg Date: 2014-05 Impact factor: 3.313
Authors: M Irem Baharoglu; Charlotte Cordonnier; Rustam Al-Shahi Salman; Koen de Gans; Maria M Koopman; Anneke Brand; Charles B Majoie; Ludo F Beenen; Henk A Marquering; Marinus Vermeulen; Paul J Nederkoorn; Rob J de Haan; Yvo B Roos Journal: Lancet Date: 2016-05-10 Impact factor: 79.321
Authors: Gregory R Stettler; Joshua J Sumislawski; Ernest E Moore; Geoffrey R Nunns; Lucy Z Kornblith; Amanda S Conroy; Rachael A Callcut; Christopher C Silliman; Anirban Banerjee; Mitchell J Cohen; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2018-10 Impact factor: 3.313
Authors: Grace E Martin; Amanda M Pugh; Ryan Moran; Rose Veile; Lou Ann Friend; Timothy A Pritts; Amy T Makley; Charles C Caldwell; Michael D Goodman Journal: J Trauma Acute Care Surg Date: 2019-04 Impact factor: 3.313
Authors: Lucy Z Kornblith; Anna Decker; Amanda S Conroy; Carolyn M Hendrickson; Alexander T Fields; Anamaria J Robles; Rachael A Callcut; Mitchell J Cohen Journal: J Trauma Acute Care Surg Date: 2019-11 Impact factor: 3.313
Authors: Paul Vulliamy; Lucy Z Kornblith; Matthew E Kutcher; Mitchell J Cohen; Karim Brohi; Matthew D Neal Journal: Platelets Date: 2020-01-27 Impact factor: 3.862
Authors: Peter Pommer; Daniel Oberladstätter; Christoph J Schlimp; Johannes Zipperle; Wolfgang Voelckel; Christopher Lockie; Marcin Osuchowski; Herbert Schöchl Journal: J Clin Med Date: 2022-05-05 Impact factor: 4.241